Aquestive Therapeutics (AQST) continues to evolve into a promising long-term investment. The company has completed its Libervant rolling NDA and received FDA approval for Exservan in ALS. In addition, Aquestive reported more than 50% growth of Sympazan shipments to retailers in Q3. What is more, the company has secured about $35M in funding from a recent secondary offering. Meanwhile, Aquestive continues to collect strong royalties and manufacturing revenue from their partnered products. Despite the recent spike in share price, I still believe AQST is undervalued and worthy of a long-term investment.
I